https://seekingalpha.com/news/4084589-teva-on-track-for-seventh-straight-day-of-gains?source=feed_tag_israel
Mar 27, 2024 - Teva Pharmaceutical (TEVA) shares are on the rise, gaining for the 7th consecutive day.
0
sa:-4695857167597984222
0
https://seekingalpha.com/article/4680308-teva-pharmaceutical-industries-potential-outweighs-concerns?source=feed_tag_israel
Mar 25, 2024 - Teva Pharmaceutical is deeply undervalued, trading at a 77% discount per my calculations. The new CEO's turnaround plan looks promising. Find out why TEVA stock is a Buy.
0
sa:-4150960373662229940
0
https://www.zacks.com/stock/news/2245567/will-corcept-cort-bank-on-korlym-in-2024-amid-stiff-rivalry?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2245567
Mar 25, 2024 - Corcept (CORT) expects its sole marketed drug, Korlym, approved for treating Cushing's syndrome, to generate incremental sales and combat stiff competition.
zc:-1327627035750226553
0
https://www.zacks.com/stock/news/2244405/gsk-follows-rivals-to-cap-out-of-pocket-inhaler-cost-in-us?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2244405
Mar 21, 2024 - GSK plc (GSK) plans to lower the prices of its entire inhaled respiratory products to $35 per month in the United States. The company intends to start this in 2025.
zc:-5021796422199526666
0
https://www.zacks.com/stock/news/2243035/astrazeneca-azn-follows-boehringer-to-cap-inhaler-cost-in-us?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2243035
Mar 19, 2024 - AstraZeneca (AZN) plans to lower the prices of its inhaled respiratory products to $35 per month in the United States. However, the company intends to start this in June 2024.
zc:-2740657310709623932
0
https://seekingalpha.com/news/4077679-teva-stock-upgraded-jp-morgan-catalysts?source=feed_tag_israel
Mar 08, 2024 - Teva Pharmaceutical (TEVA) receives an upgrade from J.P. Morgan, on upcoming positive catalysts as the bank reviews its specialty pharma coverage. Read more here.
0
sa:-5347432490541576242
0
https://seekingalpha.com/article/4673481-teva-alvotech-simlandi-approval-opens-new-generic-market-opportunities?source=feed_tag_israel
Feb 26, 2024 - Teva's stock has risen 32% since December, outperforming the SPY, buoyed by FDA approval of Simlandi, a biosimilar to Humira. Learn more about TEVA stock here.
0
sa:-4863738783062410472
0
https://seekingalpha.com/news/4071489-teva-and-jiangsu-announce-partnership-for-distribution-of-austedo-in-china?source=feed_tag_israel
Feb 26, 2024 - Teva Pharmaceutical and Jiangsu Nhwa forge a strategic partnership to enhance patient access to AUSTEDO, a drug for neurodegenerative and movement...
0
sa:735848729095779519
0
https://seekingalpha.com/article/4670634-teva-pharmaceutical-i-need-to-see-growth-before-starting-a-position?source=feed_tag_israel
Feb 15, 2024 - Teva Pharmaceutical's weak financial performance, declining revenues, and industry uncertainties make it a risky investment. Read why I rate TEVA stock a hold.
0
sa:2521424083335389399
0
https://seekingalpha.com/news/4065532-teva-stock-upgraded-piper-sandler-valuation?source=feed_tag_israel
Feb 12, 2024 - Piper Sandler upgraded Teva Pharmaceutical (TEVA) to Overweight and raised its price target to $19 from $12 per share citing valuation. Read more here.
0
sa:2780130738788668401
0